Shire Submits European Marketing Authorization Application (MAA) For Velaglucerase Alfa For The Treatment Of Type 1 Gaucher Disease

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the company’s enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease. This is the third marketing application for velaglucerase alfa that has been submitted, with previous submissions in the United States and Canada.

source : www.medicalnewstoday.com

Related News:

• Alkermes Unveils Long-Acting Injectable Proprietary Platform For Treatment Of Schizophrenia And Other CNS Disorders
• Kidney Cancer Drug Shows Promising Results
• Launch Of Ipsen’s Decapeptyl(R) 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Prostate Cancer
• Clinic Closure Leaves Indigent Dialysis Patients Looking For Treatment
• Launch Of Ipsen’s Decapeptyl 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Advanced Or Metastatic Hormone-Dependent Prostate Cancer
• Household Pesticides Contaminate Storm Runoff And Sewage Treatment Outflow
• Recordati : Silodosin Approved By The European Commission For The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia
• Auxilium Announces U.S. Food And Drug Administration Approval For XIAFLEXTM For The Treatment Of Dupuytren’s Contracture
• Two Studies Find Artefill(R) To Be A Long-Term Treatment Option For Facial Lipoatrophy
• New Treatment For Chronic Pain Condition

Details :
Submited at Wednesday, November 25th, 2009 at 1:00 pm on Endocrinology by jessica
Comment RSS 2.0 - leave a comment - trackback